中国药企2026年海外许可交易额刚刚达到1390亿美元，超过去年的纪录。
From Breakingviews - Breakingviews - COMMENTARY: China biotech's ingenuity extends to dealmaking Chinese drugmakers' 2026 overseas licensing deals just hit $139 bln, beating last year's record.
随着大型制药公司转向该国实验室寻找从癌症到肥胖的突破性成果，像恒瑞医药这样的新星正在从其发现中获取更多收益。
As Big Pharma turns to the country's labs for breakthroughs from cancer to obesity, rising stars like $44 bln Hengrui Pharma are capturing more of the upside from their discoveries.